Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 995 | 1069 | 1025 | 1157 | 1270 | 1805 |
Fund Return | -0.52% | 6.87% | 2.47% | 4.99% | 4.89% | 6.08% |
Place in category | 181 | 60 | 116 | 131 | 90 | 25 |
% in Category | 42 | 14 | 29 | 31 | 28 | 10 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
FC Responsible Global Equity Fund 2 | 1.29B | 9.14 | 6.49 | 12.49 | ||
FC Responsible Global Equity 1 Acc | 1.29B | 5.68 | 5.70 | 11.23 | ||
FC Responsible Global Equity 1 Inc | 1.29B | 5.64 | 5.43 | 11.09 | ||
FC Responsible Global Equity 2 Acc | 1.29B | 5.81 | 6.53 | 12.17 | ||
FC Responsible Global Equity 4 Inc | 1.29B | 5.95 | 7.30 | 12.94 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Liontrust Special Situations Fund R | 39.75M | -1.48 | 2.55 | 6.09 | ||
Liontrust Special Situations Fund A | 6.03M | 0.92 | 2.88 | 7.38 | ||
Liontrust Special Situations Fund I | 2.79B | 0.98 | 3.14 | 7.62 | ||
Fidelity Special Situations Fund W | 2.34B | 4.72 | 7.67 | 6.67 | ||
Fidelity Special Situations | 425.08M | -1.00 | 7.74 | 4.82 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
AstraZeneca | GB0009895292 | 6.54 | 12,118.0 | +0.56% | |
Unilever | GB00B10RZP78 | 4.20 | 49.06 | +1.45% | |
Experian | GB00B19NLV48 | 3.16 | 3,383.0 | +3.24% | |
Ashtead Group | GB0000536739 | 3.01 | 5,772.0 | +1.19% | |
GSK plc | GB00BN7SWP63 | 2.96 | 1,761.00 | +1.59% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Buy | Buy | Buy |
Technical Indicators | Strong Buy | Strong Buy | Strong Buy |
Summary | Strong Buy | Strong Buy | Strong Buy |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review